Dermira, Inc. (NASDAQ: DERM) today announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Dermira (DERM) Prices 9.81M Shares Common Offering at $13.25/ShMarch 20, 2019 6:01 AM Dermira (DERM) Could Rally to $15 or More Following Data - Mizuho SecuritiesMarch 18, 2019 8:04 AM Dermira (DERM) Climbs 48% After Reporting Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic DermatitisMarch 18, 2019 7:06 AM Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic DermatitisMarch 18, 2019 7:01 AM